• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Kolmar Group Sibling Dispute Ignites: Brother Pushes for “Board Replacement“, Sister Says “Premature”

김나영 기자

steaming@fntimes.com

기사입력 : 2025-05-15 09:00

◇ Kolmar Group’s eldest son, Vice Chairman Yoon Sang-hyun, demands restructuring of sister’s affiliate board
◇ Eldest daughter Yoon Yeo-won, CEO, pushes back: “Unjust Action ahead of earnings turnaround”

Yoon Sang-hyun, Vice Chairman of Kolmar Group (left), and Yoon Yeo-won, CEO of Kolmar BNH / Photo by Kolmar Holdings

Yoon Sang-hyun, Vice Chairman of Kolmar Group (left), and Yoon Yeo-won, CEO of Kolmar BNH / Photo by Kolmar Holdings

이미지 확대보기
[Korea Financial Times, Kim Nayoung] As Kolmar Group accelerates its transition to second-generation management, internal conflict between siblings has surfaced. This follows Vice Chairman Yoon Sang-hyun, the eldest son of Kolmar Holdings founder Yoon Dong-han, expressing his intent to restructure the board of Kolmar BNH, an affiliate led by his younger sister, CEO Yoon Yeo-won.

According to industry sources on May 13, Kolmar Holdings, the group’s holding company, submitted an application to the Daejeon District Court on May 2 to convene an extraordinary shareholders’ meeting for Kolmar BNH. The agenda includes appointing Vice Chairman Yoon Sang-hyun and former CJ CheilJedang Vice President Lee Seung-hwa as new inside directors of Kolmar BNH.

Currently, the inside directors on Kolmar BNH’s board are CEO Yoon Yeo-won and Cho Young-joo, Head of Management Planning at Kolmar BNH. CEO Yoon succeeded in being reappointed for a third consecutive term at the regular shareholders’ meeting in March last year. Her remaining term is about two years.

Vice Chairman Yoon Sang-hyun’s decision was prompted by Kolmar BNH’s poor performance and declining stock price. A Kolmar Holdings official explained, “Since 2021, Kolmar BNH has continued to struggle with poor performance and falling stock prices. The decision was made due to disappointing R&D results relative to investment and stagnant operating profit with no visible improvement.”

In fact, Kolmar BNH posted sales of KRW 615.6 billion and operating profit of KRW 24.6 billion last year. While sales reached an all-time high since the company’s founding, actual profits have dropped significantly compared to KRW 91.6 billion in 2021.

However, CEO Yoon Yeo-won’s side finds the board restructuring difficult to accept. The company believes Vice Chairman Yoon's side is attempting to remove CEO Yoon Yeo-won from her position through the board overhaul. In response, Kolmar BNH issued a statement on May 12, asserting, “Demanding changes to the CEO system and board structure is premature, as we are currently pursuing mid- to long-term strategies for a performance turnaround and enhancing corporate value.”

The statement continued, “Despite an overall slump in the health functional food industry over the past two years, we were the only company in the industry to achieve sales growth. While large-scale investments for sustainable growth have placed a considerable burden on short-term results, we have consistently maintained robust shareholder dividends and continued our shareholder return policy.”

Some observers point out that an imbalance in shareholdings between the siblings has fueled the conflict.

Currently, Vice Chairman Yoon Sang-hyun is responsible for Kolmar Holdings and the core affiliate Kolmar Korea, while CEO Yoon Yeo-won oversees Kolmar BNH, which produces health functional foods and related products. Kolmar Holdings holds a 44.6% stake in Kolmar BNH, while CEO Yoon owns only 7.8%. Vice Chairman Yoon is also the largest shareholder of Kolmar Holdings, with a 31.8% stake.

Given CEO Yoon Yeo-won’s significantly lower shareholding, the likelihood of the sibling dispute escalating into a full-fledged management rights battle is considered low. A Kolmar BNH official stated, “Given the shareholding structure, even if friendly shares are gathered, it is not a situation where a management dispute can occur. While legal action is being considered, the best outcome would be an amicable resolution. As we prepare for the extraordinary shareholders’ meeting, persuasion is our only option.”

The official added, “While current performance appears to have slowed due to an adverse base effect from the strong results in 2021–2022, it is unfair to judge CEO Yoon’s leadership based on just two years of performance,” and continued, “It’s far too hasty to push for a board reshuffle so soon after the regular general shareholders' meeting held just a month or two ago.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 LG Chem Petrochemicals Face Losses Despite NCC Restart; Advanced Materials Recovering Petrochemicals is once again LG Chem’s main concern. While earnings at its battery subsidiary and advanced materials business are improving, its petrochemicals division, which returned to profit in the first half, is expected to slip back into the red in the second half. The No. 2 naphtha cracking center (NCC) plant in Yeosu, idled for about six months, has resumed operations. But a profit recovery looks difficult as the negative inventory lag effect from falling feedstock prices and higher logistics costs weigh on results.According to financial data provider FnGuide on the 22th, the consensu 2 Hanwha Systems Raises KRW 3.4 Trillion as It Winds Down ‘Bridge’ Role in Hanwha Ocean Deal Hanwha Systems is raising KRW 3.4 trillion through a price return swap (PRS) on its Hanwha Ocean shares and the sale of its stake in the Philly shipyard in the United States. Both assets came out of Hanwha Systems’ efforts to back the Hanwha Group’s push to strengthen its shipbuilding business. The company is now expected to end its “bridge” role and concentrate on strengthening its core business through capital reallocation.According to the investment banking (IB) industry on Oct. 20, Hanwha Systems recently decided to transfer all 22,169,660 of its Hanwha Ocean common shares to Kiwoom Se 3 Hanmi Pharm Hit by Shareholder Feud, Rights Return; Next Obesity Drug Key to Rebound Hanmi Pharm is facing a double blow, a dispute among its major shareholders and the return of rights to a key pipeline asset, and has slipped into a valuation discount.While solid core profitability provides a cushion, further out-licensing of follow-up obesity drugs and a resolution of governance risk are expected to be the main turning points for a revaluation.Inheritance Tax Sparked the Feud, Now a KRW 60 Billion LawsuitHanmi Pharmaceutical Group’s operating environment is clouded from every direction, industry sources said on Oct. 18. The governance risk began after the death of founder L
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략

FT도서

더보기